650 million China Resources Pharmaceuticals commercial shares in the Inte Group is close to Zhejiang

China Resources pharmaceutical business, quite close to Zhejiang!65 million, China Resources Pharmaceuticals Commercial, equity in TheIt Group
On September 25, Zhejiang Inte Group announced that it intends to raise no more than 650 million yuan through a non-public offering of shares, and that the number of shares issued in private will not exceed 20% of the total share capital of the previously issued company. China Resources Pharmaceuticals Business Group, fully subscribe to the Inte Group's shares in this non-public offering.
the completion of this issue, according to the maximum number of issues, China Resources Pharma commercial holding a stake in the Inte Group will reach 16.67 percent, becoming a shareholder of more than 5 percent of its shares.
the Inte Group, which is also a giant.National Pharmaceutical Batch Top 100, ranked 13th
public information shows that the predecessor of Inte Pharmaceuticals was founded in July 1950 Zhejiang People's Pharmaceutical Company;
Inte Pharmaceuticals to operate drugs, Traditional Chinese medicine, biological devices as the main business, subordinate to Zhejiang Inte Pharmaceutical Co., Ltd., Zhejiang Inte Pharmaceuticals Co., Ltd., Zhejiang Medical Devices Co., Ltd. and other more than 30 member enterprises, sales network throughout Zhejiang.
revenue for 2017 was 18.907 billion yuan, with total assets of 9,083 million yuan and owner's equity of 1,905 million yuan at the end of 2017. Ranked 13th in the Commerce Department's 2017 Top 100 Drug Approval List.China Resources North-South commercial access road, will soon open
and China Resources Pharmaceutical Business, Is China Resources Pharmaceutical Group whowished large-scale pharmaceutical circulation enterprises, China Resources Group first-level profit center. By the end of 2017, China Resources Pharmaceuticals had 183 subsidiaries in 27 provinces (autonomous regions and municipalities directly under the central government), including 15 provincial commercial companies.
China Resources Pharmaceutical Business in Zhejiang Province, there is only one municipal subsidiary: China Resources Luzhou Pharmaceutical Co., Ltd. In the country's 15 provinces set up provincial subsidiaries, covering Guangdong, Shandong, Jiangsu, Henan, Anhui, Black, Ji, Liao and other provinces, opened up China's important pharmaceutical market north-south access, Zhejiang more vacancies.
China Resources Pharmaceuticals' $650 million stake in Inte Pharmaceuticals may be a strategic investment, and is likely to be a preparation for the establishment of a bridgehead in Zhejiang Province.period of change, giants and small and medium-sized enterprises different living methods
this year, the pharmaceutical circulation industry integration speed has accelerated significantly. The era of large enterprises has come, mergers and acquisitions to restructure small and medium-sized commercial companies are progressing rapidly. Small and medium-sized drug batch into large enterprises, sharing the brand of large enterprises, network resources, accelerate the integration of the company's national market.
, there is also fierce competition between large batches. China Resources pharmaceutical business this time with the industry's foreign investment, showing that large enterprises are also in a collective group, the hope in the pharmaceutical circulation market has a more solid foothold.
reshaping the pharmaceutical circulation market, small and medium-sized enterprises are struggling to survive, large enterprises are busy occupying the market - projecting an ecological map of the pharmaceutical industry during the period of change. (Seber Blue)